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Chapter I
INTRODUCTION
One of the major questions of biology is how do
growthcontrolanddifferentiationfunctionin
multicellular organisms.Because of the complexity of
the task one tries to gain insights by using model
systems.Cells growing in vitro probably provide the
most widely used model systems in biology.A major
focus of animal cell biology is the question how do
factorsoutsideofthecellinfluencegrowth and
differentiation of the cell.Some of the most important
substancesin thisrespect arethe peptide growth
factors.In the studies presented here we use serum-
free derived mouse embryo cells (SFME) to investigate
growth control and differentiation in vitro.
Transforming growth factor beta (TGF-S).Peptide
growth factors are major regulators of development in
animals.They begin to act very early in embryonic2
development.(For review on peptide growth factors in
early development:Mercola et al., 1988; David et al.,
1990;Slack,1990; Marx,1991).The term "peptide
growth factor"isanincompleteandmisleading
description of substances that may actually inhibit
growth and/or cause differentiation in vivo and in vitro
depending on cell type, growth conditions etc. (Sporn et
al., 1988).
Peptide growthfactorsform genefamiliesof
closely related factors with structural and functional
similarities (Mercola et al., 1988).One of the most
intriguing of those families is the TGF-S family.The
first member of the family, now called TGF-11,was
initially discovered and purified as a factor which
inducesphenotypictransformation (morphological
transformation and anchorage independent growth) of a
nonmalignant fibroblastic cell line (Roberts et al.,
1983).To the TGF -Z gene superfamily belong the TGF-11
through 5, the inhibins, activins, the decapentaplegic
gene, and the Mallerian inhibiting substance (Massague
et al., 1990).TGF-11 is a 25,000 molecular weight,
disulfide-linked homodimer.Each chain is synthesized
as the C-terminal domain of a larger precursor that3
contains a signal sequence for translocation across the
endoplasmatic reticulum (Miyazono etal., 1988).TGF-
S1 has been purified from human and porcine blood
platelets (Assoian et al., 1983), from human placenta
(Frolick et al., 1983), and bovine kidney (Roberts et
al., 1983).The most studied TGF -13s are TGF-131, 2, and
3.In cell culture they often act similarily (Cheifetz
et al., 1987; Graycar et al., 1989), but sometimes show
marked differences (Ohta et al., 1987; Ottmann et al.,
1988;Tsunawaki et al., 1988; Jennings et al., 1988).
TGF-B causes a multitude of effects in vitro depending
on cell type and culture conditions.Although TGF-S is
growth stimulatory for some cell types, in many cases it
is a strong growth inhibitor, especially for cells of
epithelial origin, but also for T-and B-lymphocytes
(Miyazaki et al., 1989).TGF-S controls cell adhesion,
extracellular matrix protein expression, pericellular
proteolysis, and cell adhesion receptors.It can cause
or inhibit cell differentiation, depending on cell type.
TGF-i3isthought to be involved in embryogenesis,
immunosuppression, fibrosis, and oncogenesis (for review
on TGF-S: Massague et al., 1990).
Serum-free cell culture. The discovery and4
widespread availability of peptide growth factors such
as epidermal growth factor (EGF) enabled the development
of serum-free cell culture, where serum is replaced by
growth factors, binding proteins (e.g. transferrin and
albumin), attachment proteins(e.g.fibronectin) and
otherproteins (Barnes et al., 1987; Barnes et al.,
1980).Serum-free cell culture in turn is a powerful
tool to study the action of peptide growth factors.
Those studies reveal how such factors influence growth
and differentiation of various celltypes,thereby
providing models of what may happen in vivo.
One of the insights gained by serum-free cell
culture is that serum can inhibit growth of various cell
types (Ambesi-Impiambato et al., 1980; Loo et al.,1987).
The inhibition may be a specific response to some
hormone or the result of some unspecific cytotoxic
effect. Possible inhibitory activities present in
serum arehormones or hormone-like substances such as
TGF -f(Miyazaki et al., 1988), interferons (Chen et al.,
1988) ,interleukins (Saneto et al., 1986), 3,5,3'-l-
triodothyronine and hydrocortisone (Loo et al., 1989),
tumor necrosis factors(Sugarman et al.,1985)and
others. Lipoproteinshavebeenreportedtobe5
inhibitory (Ito et al., 1982).Proteases and protease
inhibitors may also be inhibitory.Serum amyloid A
protein has been reported to inhibit growth of several
cell types in culture (Peristeris et al., 1988).
Serum-free mouse embryo cells.If one wants to
study the effects of growth factors in cell culture, one
has usually two choices: one can use primary culture of
freshly obtained cells from an animal or one can use
established cell lines such as Balb 3T3, Bela, or PC 12.
Primary culture has the advantage that the cells are
closest to what is present in the whole animal, but
often the cell composition is heterogeneous, the cells
are not well characterized and their properties change
during culture. Established cell lines are mostly
homogeneous, in many respects well characterized, and
stable,but generally they are genetically altered,
showing gross chromosomal aberrations.
Serum-freecellculturemadeitpossibleto
establish a mouse embryo cell line that combines the
advantages of established cell lines and of primary
cultures. Serum-free mouse embryo cells(SFME) are
derivedinarichbasalnutrientformulation
supplementedwithEGF,insulin,transferrin,high6
density lipoprotein (HDL), and fibronectin (Loo et al.,
1987).They are homogeneous and stable in long term
culture and do not show gross chromosomal aberrations.
They do not lose their proliferative potential during
establishment and culture, thus they show no signs of
senescence or growth crisis as in classical serum-
containing mouse embryo cell culture.They depend on
EGF for survival and are reversibly growth inhibited by
serum or platelet-free plasma. Treatment of these
cells with serum or TGF-Z causes the appearance of glial
fibrillary acidic protein (GFAP)( Sakai et al., 1990).
GFAP is a specific marker for astroglial cells,which
are a major cell type found in the central nervous
system (CNS). These findings suggest that SFME cells
may provide insightsin astrocyte precursor growth
regulation and astrocyte differentiation.
Astrocytes.Astrocytes are the most abundant
cells in the CNS, outnumbering neurons by about 10:1.
The astrocyte lineage represents actually a family of
cell types that share biochemical and morphological
traits but diverge in functional capabilities.Even
though early on astrocytes were recognized as specific
elementsof the CNS, their diversity of functions have7
only recently been revealedand are still subject of
intense research (Kimelberg et al.,1989; Frohman et
al.,1989;Prochiantz et al.,1988).The defining
characteristicofastrocytesistheexpressionof
specific intermediate filaments whose major structural
component is the 49,000 molecular weight protein GFAP
(Eng et al., 1971). An important behavior of astrocytes
in response to pathological situations isa chronic
hyperplastic change.It is characterized primarily by
deposition of GFAP fibrills and termed gliosis. It
occurs as a response to CNS injury.
Astrocytes in cell culture.Astrocytes have been
studiedextensivelyinculture. Thishasbeen
facilitated greatly by the fact that one can easily
obtain essentially pure astrocyte primary cultures
(Hertz et al., 1982).However, the reported properties
oftheculturedastrocytesoftendiffer markedly
(Juurlink et al., 1985).This may be due to differences
in the source of the cells with respect to speciesor
region of the CNS,dissociation procedures,culture
medium,type and/or concentration of serum used in
culture, if any (Juurlink et al., 1985).The properties
of the cells may change with time in culture.8
The heterogeneity of astrocytes is illustrated in
the work of M.C. Raff and coworkers (for review: Lillien
et al., 1990).They showed that rat optic nerve primary
cell culture contains two morphologically, biochemically
and immunohistochemically distinct types of astrocytes:
type-1 astrocytes and type-2 astrocytes (Raff et al.,
1983).The studies of M. C. Raff and coworkers show how
these two types of astrocytes interact and interdepend.
Their studiesare probably the mostcomprehensive
investigations of astrocyte differentiation in vitro.
Raff and coworkers showed that type-2 astrocytes develop
from progenitor cells that have the capability to give
rise to oligodendrocytes or type-2 astrocytes.In a
serum-freeculturemediumtheprogenitorcellis
committed to the oligodentrocyte lineage.But in the
presence offetal bovine serum(FBS),optic nerve
extract or ciliary neuronotrophic factor (CNTF)they
develop to GFAP positive type-2 astrocytes (Hughes et
al., 1988). Platelet-derived growth factor (PDGF),
fibroblast growth factor (FGF), and CNTF inhibit the
differentiation of progenitor cells into
oligodentrocytes (Noble et al., 1988). PDGF promotes
divisionandmotilityandinhibitspremature9
differentiation of the oligodentrocyte/type-2 astrocyte
progenitor cell.
Astrocyte cell lines,derived from tumors or
otherwise transformed cells have been used to study
astrocyte differentiation.But these cells are often
genetically abnormal and probably reflect astrocytic
properties in vivo to a lesser extent (Bressler et al.,
1992, Hertz et al., 1985).10
Chapter II
CHARACTERIZATION OF HUMAN PLASMA GROWTH INHIBITORY
ACTIVITY ON SERUM-FREE MOUSE EMBRYO (SFME) CELLS
SUMMARY
The growth inhibitory activity of human plasma on
serum-free mouse embryo cells was investigated.Human
plasma does not inhibit SFME cells transformed with the
human Ha-ras oncogene.The activity was present in
delipidated plasma and was not dialyzable against 1 M
acetic acid.The activity could be precipitated by
methanol,boundtoconcanavalin A-agarose and was
retarded by Sephadex G-50 in 200 mM acetic acid.A
fifty to one-hundred fold purification was achieved,
although the differential inhibition of untransformed
versus transformed cells was lost in the course of the
purification.11
INTRODUCTION
SFME cells are mouse embryo cells derived in
serum-free basalnutrient medium supplemented with
epidermal growth factor(EGF),insulin,transferrin,
highdensitylipoprotein (HDL), selenium,and
fibronectin (Loo et al., 1987).These cells exhibit
several unusualcharacteristics. (i)They do not
exhibit growth crisis or gross chromosomal aberration
even in long term culture (Loo et al., 1987).(ii) In
the presence of transforming growth factor beta (TGF-S)
SFMEcellsexpresstheastrocytemarker,glial
fibrillary acidic protein (GFAP)(Sakai et al., 1990).
(iii) SFME cells are dependent on EGF for survival and
(iv)are reversibly growth inhibited by serum and
platelet-free plasma (Loo et al., 1987).
(v)Transformation of these cells with the ras or neu
oncogenes releases the cells from the growth inhibition
by serum/plasma and the EGF requirement for survival
(Shirahata et al., 1990).
Culture of the SFME cells in the presence of serum
causes a rapid growth inhibition, followed after several
weeks of culture by the outgrowth of rare, abnormal,12
hyperploid variants (Rawson et al., 1991).Exposure of
the cells to calf serum for as little as 8 h causes a
near maximal effect (Rawson et al., 1991).The behavior
of SFME cells in serum is probably not simply a toxic
response because it is reversible (Loo et al., 1987;
Rawson et al., 1991) and the cells arrest in the G 1
phase of the cell cycle in the presence of 10 % calf
serum (Rawson et al., 1991).In medium with 10 % serum,
incorporation of thymidine into DNA and the activity of
thymidine kinase(anS-phase dependentenzyme)is
reduced, while incorporation of amino acids into protein
is not (Rawsonet al., 1991).These results suggest
that the growth inhibition may be a response of the SFME
cells to a physiological mediator.
Glucocorticoid and thyroid hormones may contribute
to the inhibitory activity of serum, but Loo et al.
(1990) have shown that at least one additional factor
must be involved.Heat inactivation of serum or plasma
(56°C,30minutes)doesnotdiminishthegrowth
inhibitory activity.Sera from a variety of species,
including calf,adult, and fetal bovine sera, human
serum and plasma, and mouse serum are inhibitory (Loo et
al., 1987).Calf serum is of somewhat higher inhibitory13
activity than calf plasma (Loo et al., 1987).
TGF-E, is a strong inhibitor for many types of
cultured cells, especially those of epithelial origin
(Miyazaki et al., 1989).However, growth inhibitory
effects of TGF-S on SFME cells are small and variable,
even though TGF-S has a profound differentiating effect
on these cells.We could not reproduce the inhibitory
effect of serum with either TGF -Z or other peptide
factors including interferons and interleukines. Still,
the recent finding of peptide growth inhibitors such as
TGF -Z and others(Miyazaki et al.,1989)encouraged
speculations that such factor(s) may be responsible for
the growth inhibition we see with SFME cells in the
presence of serum or plasma.
Because serum lipoproteins are potentially growth
inhibitory (Ito et al.,1982) we used delipidated human
plasmaasstartingmaterialtostudythegrowth
inhibitory activity of plasma.We find evidence that a
peptide factor may be responsible for the inhibition.14
MATERIALS AND METHODS
Materials. Powdered medium formulations and
antibiotics were obtained from Grand Island Biological
Company(GrandIsland,NY);sodiumseleniteand
ethylenediaminetetraacetate(EDTA)wasfromFisher
Scientific (Pittsbugh, PA); sodium bicarbonate powder
('Baker Analyzed'reagent)was from J.T.Baker Inc.,
(Phillipsburg,NJ);4-(2-hydroxy-ethyl)-1-piperazine-
ethanesulfonic acid (HEPES) was from Research Organics,
Inc.(Cleveland, OH).Gelatin-sepharose was obtained
from Pharmacia Chemicals(Piscataway,NJ). Bovine
insulin, human transferrin, trypsin, soybean trypsin
inhibitor were from Sigma Chemical Corp. (St.Louis, MO).
Mouse EGF was obtained from Upstate Biotechnologies
(Lake Placid, NY).Plasticware for cell culture was
from Falcon.Membrane tubing (Spectra/Por) was from
Spectrum medical industries,Inc.(Los Angeles, CA).
ConcanavalinA-agarosewasfromBethesdaResearch
Laboratories, Inc. (MD) and Sephadex G-50 was from Sigma
Chemical Corp. (St.Louis, MO).Water for reagents was
passagedthrough aMilli-Q (Millipore) water
purification system immediately prior to use.15
Cell culture.Culture of Balb SFME cells was
essentially as described in detail in Loo et al., (1989a
and b).Derivation and characterization of oncogene
transformed Balb SFME cells was described in Shirahata
et al., (1990); the Ha-ras-myc c1.1 SFME cell line was
derived by cotransfecting pSVc-myc and pUCEJ6.6, which
contains the human Ha-ras gene(Chang,1987).SFME
cells were grown in a basal nutrient formulation of a
1:1mixtureofDulbecco-modifiedEagle'smedium
containing 4.5 g/L glucose and Ham's F 12(F 12:DME
medium), supplemented with 1.2 g/1 sodium bicarbonate,
15 mM HEPES (pH 7.4), 200 U /ml penicillin, 200 µg /ml
streptomycin, 25 µg /ml ampicillin, mouse EGF (50 ng/ml),
bovine insulin (10 Ag/m1), human transferrin (10 Ag/m1),
human HDL (10 µg /ml), and sodium selenite (10 nM) on 75
cm2 surface tissue culture flasks precoated with bovine
or human fibronectin (10 µg /ml).
Cells were grown in a humified 5% CO2-95% air
atmosphere at 37°C. Trypsinization and plating in
serum-free culture was accomplished by short exposure at
room temperature to 0.25%crude trypsin in1 mM
EDTA/PBS withoutcalcium or magnesium followed by
dilution of the cells into soybean trypsin inhibitor16
solution (1 mg/ml in F12:DME medium).Cells were then
centrifuged, resuspended into F12:DME, and counted. The
appropriate cell number was plated in 1 ml of prewarmed
medium in culture vessels previously precoated with
fibronectin and preincubated in the incubator (5's CO2-
95t air atmosphere at 37°C) for approximately 15 minutes
with the remaining portion of medium (final volume 2
ml).Insulin, transferrin, EGF, and HDL were added
directly from concentrated stocksinto the culture
medium immediately after plating the cells.
Insulin stock was1 mg/mlin 20 mM HC1 and
transferrin stock was 2.5 mg/ml in F12:DME medium; both
were filter sterilized.EGF was reconstituted in PBS
(50 µg /m1).Fibronectin stocks (about 1mg/m1 in 50 mM
Tris pH 7.5, 4 M urea) were filter sterilized.
Stocks of insulin, transferrin, EGF, and fibronectin
were stored at -86°C in aliquots until needed, then
stored at 4°C after thawing.HDL was prepared for cell
culture as described in Loo et al.,(1989).Fibronectin
waspreparedbygelatin-affinitychromatography
(Rouslathi et al., 1982, Loo et al.,1989).
Growth inhibition bioassay.Cells were detached
from the stock flask by trypsinization.Trypsin was17
inactivated by addition of trypsin inhibitor solution
followed by fresh nutrient medium.SFME cells were
centrifuged,resuspended,counted and plated into a
finalvolumeof2mlofnutrientmedium,and
supplemented with EGF, insulin, transferrin, HDL, sodium
selenite,bicarbonate and antibioticsas described
above,with plasma,serum orcolumnfractionsas
indicated.The untransformed SFME cells were plated at
lower density (0.5x105/35mm dish) than the transformed
SFME(1x105/35mmdish),becausetheygrew more
vigorously.In some experiments 250 ng/ml oleic acid
was added, because it improved the growth of the SFME
cells.Cell number was determined after 5 days of
incubation, or otherwise at the indicated times after
plating, by counting suspensions of trypsinized cells
using a Coulter particle counter.Average variation of
single determinations from the mean was less than eleven
percent.
Dialysis of plasma and plasma fractions. Membrane
tubing (3500 M.W. cutoff)was boiled for about ten
minutes in 1 mM EDTA, 2% bicarbonate solution and rinsed
with Milli-Q water. Tubes were stored in boiled water at
4°C.Dialysis was performed at 4°C with stirring.18
Dialysis conditions forthe growth inhibitory
activity in human delipidatedplasma were establishedas
follows:1.5 ml aliquots of delipidatedhuman plasma
thatcontained the KBr from thedelipidation process
were dialyzed against 1.5 liter of 10mM HEPES, pH 7.0,
0.15 M NaCL, 0.1 mM EDTA.2 ml of human plasma that
were the source of the delipidatedplasma was also
dialyzed against 2 liters of10 mM HEPES, pH 7.0, 0.1 mM
EDTA, 0.15 M NaCl. Dialysisoccured over a period of 24
hours with three changes ofbuffer after 6 hours of
dialysis.The samples were sterile filtered(2 Am) and
tested on Balb SFME andHa-ras-myc C1.1 Balb SFME in
200, 100, 50, and 25 mircoliterdoses.Cell number was
determined after 5 days.
Preparationofdelipidatedhumanplasma.
DelipidatedhumanplasmawaspreparedbyKBr
ultracentrifugation of freshlydrawn citrated human
plasma after plateletswere removed by centrifugation.
The procedure for HDL preparationis described in Loo et
al. (1989).The lower phase of the lastcentrifugation,
containingthe delipidated plasma,was pooled and
dialyzed extensively against10 mM HEPES, pH 7.0, 0.15
M NaC1 using a 3.5 KD cut-offtubing.(Dialysis was19
performed over several days with multiple buffer changes
untilsaltwasdiluted morethan105-fold). The
dialyzed,delipidated plasma wasthen heat-treated
(60°C)for30minutestoachieveclottingand
inactivation of complement.Delipidation using organic
solvents was performed according to Rothblat et al.,
(1976).
Methanolprecipitationofhuman" plasmaand
delipidated human plasma.To delipidated human plasma,
at4°C,wasadded1/3plasma volumeofice-cold
methanol.This was mixed quickly and left on ice for 1
hour. The precipitate was centrifuged (4°C, 15 minutes,
30,000 g),the supernatant discarded and the pellet
resuspended in 10 mM HEPES, pH 7.0, 0.15 M NaC1 (1/3 of
the original plasma volume).This was left at 4°C
overnight to redissolve.Remaining insoluble material
was centrifuged (30,000 g, 15 minutes, room temperature)
and the dissolved precipitate was sterile-filtered (0.2
Am).
ConcanavalinA-agarosechromatography. A
concanavalin A-agarose column (31 cm x 2.5 cm, about 150
ml bed volume) was equilibrated by washing extensively
(e.g. 2 1) with running buffer (10 mM HEPES, pH 7.0,20
0.15 M NaC1).The sample was applied and the column
washed with about 300 ml running buffer at 16 ml/h.
Fractions were eluted with 200 ml1 M a- methyl -D-
mannoside in running buffer (20 ml/h).Final wash was
to baseline of A280(about 0.1) with runnning buffer.
All runs were at 4°C.Storage buffer was 20 mM Tris,
0.15 M NaC1, 1 mM CaC12, 1 mM MgCl2, 1 mM MnC12, 0.02 %
NaN3, pH7.4.
Sephadex G-50 chromatography.Eluate fractions
from concanavalin A chromatography were pooled and
dialyzed extensively against 200 mM acetic acid.The
dialysatewasvacuum-concentratedabouttenfold,
redialyzed against200 mM acetic acid and sterile
filtered (0.2 Am).A 2 ml sample was applied to a G-50
Sephadex column (1 cm diameter, 45 cm length, 35 ml bed
volume) equilibratedin200mMaceticacid.
Chromatography was developed with 200 mM acetic acid (5-
6 ml/h, 4°C).1 ml fractions were collected.21
RESULTS
Inhibitory activity is not dialysable.Extensive
dialysis against 10 mM HEPES, pH 7.0 or pH 8.0, 0.15 M
NaC1, 0.1 mM EDTA or DME, pH 7.4, did not remove the
growthinhibitoryactivityfromdelipidatedand
nondelipidated human plasma. 50% inhibition with
respectto control(no plasma added)wasseen at
approximately 2.5mg/mlprotein(seefigure1).
Dialysis against 10 mM HEPES, pH 6.0, 0.15 M NaC1, 0.1
mM EDTA reduced the activity slightly (50 % inhibition
at 3.5 mg/ml).Dialysis against low salt solutions
reduced the activity significantly.For example, after
dialysis against buffer containing 0.05 M NaC1, 50 %
inhibition occurred at 4.5 mg/ma protein.The same
protein concentration caused only a 35% inhibition after
dialysis with no salt present in the dialysis buffer.
This may indicate that the activity is a protein or is
bound to a protein that needs salt for solubilization.
Dialysis of freshly drawn citrated human plasma against
10 mM Hepes, pH 7.0, 0.15 M NaC1, 0.1 mM EDTA reduced
theinhibitory activity,butasignificant amount
remained.The procedure possibly removed dialyzable22
inhibitorslike triiodothyronine or hydrocortisone.
Delipidated human plasma dialyzed against 10 mM HEPES,
pH 7.0,0.15 M NaCl,0.1 mM EDTA was of the same
inhibitory activity as undialyzed undelipidated plasma.
Delipidation may remove growth promoting activities
including some growth-stimulatory lipoproteins.Most
activity was lost through reduction or omission of the
salt content of the buffer.Extensive dialysis of
delipidated human plasma against 1 M acetic acid did not
remove the inhibitory activity from the plasma. In this
propertytheactivity resemblesthatofmany low
molecular weight peptide growth factors which are also
stable in acidic conditions.
The inhibitory activity precipitates out in low
ionic strength;purification using methanol preci-
pitation.Delipidated human plasma containing 10.17 M
KBrfromthe delipidation processwasextensively
dialyzed against water(100 ml plasma were dialyzed
against 4 liter water with 9 changes over 40 hours).
The plasma was stored at -20°C before further use. After
thawing,the precipitate that formed was removed by
centrifugation and the pellet resuspended in 10 mM
HEPES,pH7.0,0.15 M NaC1,0.1mMEDTA. The23
resuspended precipitate was tested on SFME and Ha-ras-
myc SFME in a 4 day growth assay.The resuspended
precipitate was strongly inhibitory for SFME cells but
not inhibitory for the transformed cells(data not
shown).This suggested that precipitation using an
organic solvent, e.g. methanol or ethanol, that lowers
thedielectricconstantofwater might providea
preliminary purification of the inhibitory activity.
We found that 339v/v methanol quantitatively
precipitatedthegrowthinhibitoryactivityfrom
nondelipidated and delipidated human plasma. The pellet
could be redissolved in HEPES saline (10 mM HEPES, pH
7.0, 0.15 M NaC1) and was enriched 2-3 fold in specific
activity with respect to protein concentration(see
figure 2).This procedure left all the albumin in the
supernatant, asjudgedbypolyacrylamide gel
electrophoresis. It is possible that the 33 tv/v
methanol liberates some of the otherwise toxic lipids
into the supernatant.Delipidation of the human plasma
proteins according to the method of Rothblat et al.
(1976), which consists of precipitation of the proteins
in ten times the plasma volume of acetone-ethanol (1:1
by volume) and a subsequent wash of the precipitate with24
diethyl-ether, did not decrease the inhibitory activity
of the resuspended plasma proteins (data not shown).
The inhibitory activity in human plasma binds to
concanavalin A-agarose and can be eluted with a-methyl-
D-mannopyranoside.Concanavalin A is a lectin that
binds structures containing alpha-linked mannose, such
asinN-acetylglucosaminylcoredisaccharidein
asparagine-linked glycoproteins. Delipidated human
plasma was methanol precipitated, resuspended, filtered
(0.2 Am) and chromatographed on concanavalin A-agarose.
Thechromatogramconsistedofthreepeaks. The
fractions with higher Ano values in the first peak were
turbid. This peak probably representsaggregated
material that cannot bind to the matrix.About 50 % of
the total input protein was in the second peak, which
contained material that was retarded by the column.
This peak did not contain any measurable inhibitory
activity(figure3)and consisted mainly of gamma-
globulin (judged by SDS polyacrylamide gel
electrophoresis). Some inhibitory activity was found in
the first peak, but the bulk of activity was eluted as
a third peak with a- methyl -D- mannoside. (First and
second peak fractionswere assayed directly after25
sterile filtration (2 Am), eluate peak fractionswere
dialyzed extensively against 10 mM HEPES, pH 7.0, 0.15
M NaCl, sterile filtered and assayed).The first peak
and the third (eluate) peak were of about the same
specificinhibitoryactivity(figure4). The
purification of activity was approximately 1.5-2 fold
with respect to protein concentration of the methanol
precipitate of delipidated human plasma (figure 4).The
material of the first peak and the eluate peak was also
inhibitory to the transformed cells, but a distinct
differential remained between effects on the normal and
transformed cells.
Further purification of the inhibitory activity
from concanavalin A-agarose chromatography by Sephadex
G-50 chromatography. Eluate fractions from concanavalin
A-agarosechromatographyofthe33%v/v methanol
precipitate of human delipidated plasma were dialyzed
against 200 mM acetic acid and vacuum concentrated to
A280 of 40.2 ml was run on a Sephadex G-50 column (1x45
cm) in 200 mM acetic acid.Fractions (1m1) were pooled
as indicated (figure 5), because the inhibitory activity
was expected to be spread over several fractions.The
pools were chosen so they would establish,ifthe26
activity was excluded by the gel (molecular weight>circa
30,000) most proteins in the concanavalin A-agarose
eluate as judged by gel electrophoresis), or retained by
it.Pools were vacuum concentrated and assayed on
untransformed SFME and Ha-ras-mvc c1.1 SFME cells.The
activity was present in the retarded portion of the
chromatogram, whereas the majority of proteins were in
the void volume.When the Sephadex G-50 column was
developed in 10 mM HEPES, pH 7.0, 0.15 M NaCl, instead
of acetic acid, the inhibitory activity chromatographed
with the excluded material (data not shown).In another
experimenteluatefractionsoftheconcanavalin A
chromatography were pooled and chromatographed on the
Sephadex G-50 column in 200 mM acetic acid.Fractions
that followed the peak of unretardedmaterial (where
the inhibitory activity was to
fractions) of three column runs
be expected, about 10
were collected, vacuum
concentrated, dialyzed against 50 mM acetic acid and
assayed in a bioassay. This G-50 preparation was
strongly inhibitory to Balb SFMEcells with50
inhibition requiring about 20 µg /ml protein.Low doses
of acetic acid (<2.5 mM) in the culture medium were not
inhibitory.It was also inhibitory to the transformed27
cell line with 50 % inhibition at about 40 pg/ml.Thus,
the differential effect was essentially lost in this
purification.It cannot be excluded that the inhibitory
activity in human plasma changes its behavior during its
purification, because other, interacting substances have
beenlost(see'DISCUSSION'below). Still,the
activity,like the activity in unfractionated human
plasma,was largely susceptible to inactivation by
heating to 100 °C for three minutes (see figure 6).
Inactivation by boiling could be explained by loss of
tertiary structure of a protein, however, we could not
demonstrate that the activity is destroyed by digestion
with proteases (data not shown).Further, it was not
inactivated by reduction with 50 mM dithiothreitol at pH
8.0, a condition that would inactivate TGF -1(Assoian et
al., 1983).The untransformed SFME cells are normally
rather elongated cells,but became very small and
rounded in the presence of the G-50 preparation, and
stuck tightly to the culture dish.The cells exhibited
this striking morphology even at lower doses, where the
preparation did not inhibit the cells from several
rounds of doubling.
It should be noted that small amounts of humanplasma and all preparations described here
growthstimulationofSFMEcells.
examination of the cells suggested that
because of better attachment of the cells.
28
caused some
Microscopic
this may be29
DISCUSSION
The use of serum-free cell culture to study
growth inhibiting activities in plasma /serum.Serum-
free cell culture opens the possibility to study growth
inhibitory activities present in blood plasma or serum
that may otherwise not be detectable.Cell lines that
have been derived in serum-containing media often lose
their responsiveness to these factors.The use of a
serum-free derived cell line circumvents this problem.
However, serum-free cell culture can also pose problems
in the study of growth inhibitory activities, since the
cells are more sensitive to perturbing substances than
cells growing in serum-containing media.Especially
fatty acids and other lipids may harm the cells if not
buffered by proteins such as albumin.The use of
delipidated plasma or serum for fractionation procedures
may eliminate possible unspecific growth inhibition by
lipoproteins and/or lipids that are released.Since
plasmaandserumalsocontaingrowthpromoting
activities that can overshadow the inhibiting activities
itis important to provide the most optimal growth
conditions for the cells in a bioassay of the growth30
inhibiting activities.One should try to maximize the
mitoticpotentialofthecellsbyprovidingall
supportive activities plasma or serum may offer.In our
case beneficial components included attachment factors
and some lipids, and were provided by fibronectin and
250 ng/ml oleic acid.
Nature of the growth inhibiting activity.We
achieved a 50 to 100-fold purification of the growth
inhibiting activity from delipidated human plasma.In
the course of this purification the activity behaved
like a macromolecular entity (molecular weight>3.5 KD).
It was not dialysable, even against 1 M acetic acid,
which disrupts binding of many ligandsto binding
proteins.It could be precipitated by 33v/v methanol,
which precipitates most plasma proteins with the
exception of albumin. It bound to concanavalinA-
agarose,a lectin matrix,and it therefore must be
either glycosylated or else bound very tightly to a
glycosylated entity.The activity that was retained by
Sephadex G-50, was not dialysable in 200 mM acetic acid
and was inactivated by boiling for three minutes.
In the course of the purification the differential31
growthinhibitoryeffectonuntransformedversus
transformed SFME cells disappeared, and in the final
preparation there was little difference in activity on
normal and transformed cells.It is possible that our
fractionation procedures removed factors that allow the
transformed cells to overcome the inhibitory activity,
while the untransformed cells are not responsive to
these substances.Another explanation would be that
several growth inhibitory activities are present in the
plasma, one or several with a differential effect and
others without a differential effect.We may have
purified an activity without the differential effect.
This possibility must be considered, since the yield of
activity in our procedure is low (4% total recovery of
inhibitory activity).
Thefinalpreparationdidnotinducethe
expression of GFAP, as does TGF -I, nor did it prevent
cell death in absence of EGF (data not shown). Although
TGF -Z causes expression of astrocyte markers in SFME
cells, it does not prevent exponential growth of these
cells. Since astrocytes are obviously under tight
growth control in vivo, a mechanism must exist that
exerts this control.An astrocyte-specific mitogen32
inhibitor has been identified ( Nieto-Sampedro ,1988) in
brain extracts that is related to the EGF receptor.
Interestingly,a liver extract also containing EGF
receptor crossreactivity was also growth inhibitory to
astrocytes.We observed an activity in conditioned
serum-free medium of the human liver cell line HepG2
that had a growth inhibitory effect on the untransformed
SFME cells but not on transformed SFME cells (data not
shown).The relationship of the inhibitor reported by
Nieto-Sampedro and the activity in the HepG2 conditioned
medium or in plasma we studied is not known.33
Figure 1:Bioassay of human plasma inhibitory activity
after dialysis.Counts of Balb SFME cells were carried
out after 5 days.Cells were plated at 105 cells/35 mm
dish.
triangle:undialyzed human plasma in culture medium.
circle: human plasma, dialyzed against 10 mM HEPES,
pH 7.0, 0.15 M NaCl, 0.1 mM EDTA in culture
medium.
square: delipidated human plasma, dialyzed against 10
mM HEPES pH 7.0, 0.05 M NaC1, 0.1 in culture
medium.7
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Figure2: Bioassayofmethanolprecipitateof
delipidated human plasma.Balb SFME cells were plated
at 0.5x106, Ha-ras-myc clone-1 SFME were plated at 1x106
cells\35 mm dish.Cell count was after 5 days.
squares:delipidated human plasma on Balb SFME cells.
circles:resuspended methanol precipitate on Balb SFME
cells.
triangle: resuspended methanol precipitate on Ha-ras-
myc-clone 1 cells5
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Figure3: Bioassayofinhibitory activity after
concanavalin A-agarose chromatography of human plasma
inhibitory activity in 33v/v methanol precipitate.
Balb SFME cell number was determined after 4 days of
growth.
circle: peak I
triangle: peak II
square: peak III (a-methyl-D-mannoside eluate)4
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Figure 4:Bioassayofinhibitoryactivityof
concanavalin A-agarose eluate.Balb SFME cells were
plated at0.5x106 cells/35 mm dish,the Ha-ras-myc
transformed cells at lx106cells/35 mm dish.Cells were
counted after 5 days of growth.
square: resuspended methanol precipitate of
delipidated human plasma on untransformed
cells
circle: dialyzed peak fraction of eluate on
untransformed cells
triangle: dialyzed peak fraction of eluate
on transformed cells7
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Figure 5:Molecular-sieve chromatography of growth
inhibitor fraction.Concanavalin A eluate of 33%
methanol precipitate of human delipidated plasmawas
dialyzed against200mMaceticacid,vacuum
concentrated and chromatographed on a 1x45 cm-column of
Sephadex G-50 in 200 mM acetic acid.0
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Figure 6:Dose-response curves of the growth inhibitory
activityafterpurification bySephadex G-50gel
chromatography in 200 mM acetic acid. Balb SFME cells
were plated at 0.5x106/35 mm dish, Ha-ras-mvc clone-1
SFME cells were plated at 1x106/35 mm dish.
Fractions were in 50 mM acetic acid.Identical volumes
of 50 mM acetic acid were added to control plates.A
portion of the preparation was boiled for three minutes
and then tested;
full circles:Ba1bSFME/G-50 prep
full square: Ba1bSFME /boiled G-50 prep
empty triangle: Ha-ras-myc clone-1 SFME/G-50 prep44
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Table 1:Bioassay of fraction pools of Sephadex G-50
chromatogram. Fraction pools are as indicated in
figure 5.Balb SFME cells were plated at 0.5x105, Ha-
ras-myc c1.1 SFME cells at 1x105.Counts were after
five days.46
TABLE 1:
Bioassay of fraction pools of Sephadex G-50
chromatogram.
pool A
pool B
pool C
pool D
Balb SFME Ha-ras-myc c1.1
Cell Protein Cell Protein
number (km/m1) number (A2o/m1)
(t of
control)
(t of
control)
130 0.27 79 0.27
15 0.2 50 0.2
57 0.05 43 0.05
33 0.04 42 0.0447
Chapter III
IDENTIFICATION OF A TGF -1REGULATED, BRAIN-SPECIFIC
mRNA IN SFME CELLS
SUMMARY
Using the technique of differential screening of
a cDNA library a calf serum- and TGF -Z- regulated mRNA
species was identified in SFME cells.This RNA is
brain-specific and approximately 8.5 kilobases long.
Picomolar quantities of TGF-S caused an increase of this
message in SFME cells within four hours.This increase
was reversed when TGF-S is removed from the culture
medium.
INTRODUCTION
Serum-free mouse embryo (SFME) cells are derived in
medium in which serum is replaced with growth factors
and other supplements. They display unusual properties.
(i)They do not lose proliferative potential or show48
gross chromosomal aberration upon extended culture, (ii)
they depend on epidermal growth factor for survival ,
and (iii) are reversibly growth inhibited by plasma and
serum (Loo et al., 1987; Loo et al.,1989 a; Loo et al.,
1989 b; Loo et al.,1990).
Treatment of SFME cells with serum or transforming
growth factor beta(TGF -1)causes the appearance of
glial fibrillary acidic protein (GFAP) and GFAP mRNA
(Sakai et al.,1990).GFAP is a specific marker for
astrocytes (Lazarides, 1982; De Vellis et al., 1986;
Morrison et al.,1985).In addition to GFAP,TGF-13,
regulates the protease inhibitor cystatin C in SFME
cells (Solem et al.,1990).
Transforming growth factor beta, a serum component
(Bjornson et al., 1982; Masui et al., 1986) is a peptide
that influences differentiation of various cell types in
vitro and in vivo,particulary those of mesodermal
origin.However, reports on effects of TGF-E on cells
of neuroectodermal origin are scarce.This is also true
for cells of the astrocytic lineage.TGF-Z1 and TGF -f2
have been shown to suppress rat astrocyte autoantigen
presentation and antagonize hyperinduction of class II
major histocompatibilty complex antigen expression by49
interferon-gammaandtumornecrosisfactor-alpha
(Schluesener et al., 1990).Robertson et al.(1988)
found that TGF -fstimulated phosphoinositol metabolism
and translocation of protein kinase C in cultured
astrocytes.Saad et al.(1991) observed an effect of
TGF-S2 on the regulation of neural recognition molecule
expression by cultured astrocytes.The finding of our
laboratorythatTGF -Zinduces GFAPinSFMEcells
suggeststhat TGF-S may play a rolein astrocyte
development in vivo. TGF-S may contribute to the
phenomenon of gliosis, the hypertrophy and increase in
GFAP in astrocytes in response to injury or chronic
disorders of the brain. Recently,TGF -Ihas been
identified by immunochemistry in the brain tissues of
patients with aquired immune deficiency (butnot in
control brain).The TGF-Sstaining was localized to
astrocytes(as well as cells of monocytic lineage),
especially in areas of brain pathology (Wahl et al.,
1991).These results stress the importance offurther
investigating the action of TGF -Z on cells ofthe
astrocytic lineage.It is interesting to investigate
whether other brain specific messages are induced by
TGF-S in SFME cells.Such a message may serve as50
additional marker of differentiation.It may provide
further insights into brain specific action of TGF-S.
We used the technique of differential screening
of a cDNA library to identify a novel,large mRNA
species that is reversibly induced byserum and TGF-S in
SFME cells and that is brain specific.51
MATERIALS AND METHODS
Cell culture and RNA isolation.Procedures for
culture of Balb/c SFME cells have been described in
detail in Loo et al. (1987), Loo et al. (1989 a), Loo et
al. (1989 b).RNA isolation was done as follows.Cells
growing in plastic dishes were washed twice with ice-
cold PBS.They were then gently scraped off the dish
(in 1-2 ml of PBS) with a rubber policeman and pelleted.
Cells were resuspended in 140 mM NaC1, 1.5 mM MgC12, 10
mM Tris-HC1, pH 7.6, 200 µg /ml heparin (Sigma Chemical
Company, MO) and lysed by adding 0.5 t Nonidet P-40
(Sigma Chemical Company, MO).After brief mixing the
lysate was centrifuged at 4000xg for 10 min.1t SDS and
10 mM EDTA was added to the supernatant followed by
extraction twice each with phenol, phenol/chloroform
(1:1), and chloroform/isoamylalcohol (24:1), and ethanol
precipitation. Residual DNA was removed with RNAse free
DNAse I in the presence of vanadyl riboside complex
(both from Bethesda Research Laboratories, MD).Poly A-
containing RNA was isolated as described by Davis et al.
(1986).Mouse tissue mRNA was obtained from Clonetech
Inc.,(CA).52
Northern blot analysis. RNA (20 µg /lane) was
fractionated by electrophoresison formaldehyde/1.2 %
agarose gels and transferred overnight to nitrocellulose
membranes(0.45 gm pore size, Schleicher & Schuell,
N.H.), as described by Maniatiset al.(1982).DNA
probes were 32P-labeled by random primer extensionusing
akitfromBoehringerMannheim,a-32P-radiolabeled
nucleotides(3000Ci/mmol)werefrom NEN Research
Products,(DE).Membranes were prehybridized for 4 hr
and then hybridized with probe(about106cpm /ml)
overnight in 10 % dextran sulfate (Pharmacia, N.J.),40
formamide, 4x SSC, 10 x Denhardt's solution,0.2 M
Tris-C1, pH 7.4, 200 µg /m1 boiled sonicatedsalmon sperm
DNAat42°C(G+Ccontent<50%)or57°C(G+C
content >50 %).Filters were washed three times in 2x
SSC, 0.1SDS at room temperature for 15 minutes, then
twice in 0.1 x SSC, 0.1 % SDS at 65°Cfor 15 minutes.
Autoradiography was carried outon Kodak X-Omat AR film
from overnight to several days at -80°C.
Southern blot analysis.A Southern blot with
restriction enzyme digestedmouse genomic DNA was
performed using mouse Genoblot from ClonetechInc.,(CA)
according to the manufacturers directions.53
Differentialscreening. A cDNA library was
prepared from mRNA of SFME cells, grown in serum-free
medium supplemented additionally with 10 t CS for 24 h,
using a cDNA synthesis kit (Pharmacia, N.J.).First-
strand cDNA synthesis was preformed with Moloney murine
leukemia virus reverse transcriptase and oligo d(T)1248
asprimer. Second-strandsynthesisinvolveda
modification of the procedure of Gubler and Hoffman
(1983).To the blunt-ended cDNA an EcoRI/NotI adaptor
was ligated to each end.The cDNA was ligated to lambda
gtll arms, packaged and plated using E.Coli strain
Y1090 as host.The library contained over 2.4x106
unique clones (average size smaller than 200 bp; maximal
size 3 kb).Radiolabeled, single-stranded cDNA probes
were synthesized using as template mRNA from SFME cells
cultured with or without 10 % CS for 24 h.Specific
activities were 1-5x107 cpm/Ag mRNA for both probes.
Differential screening of phage plaques transferred to
duplicate nitrocellulose filters was performed using
about5x105cpm/mloftheradiolabeledprobesin
hybridization buffer containing 10 % dextran sulfate, 40
% formamide, 4 x SSC, 10 x Denhardt's solution, 0.2 M
TrisCl, pH 7.4, 10 µg /ml poly (A)(Pharmacia), and 20054
µg /ml sonicated salmon sperm DNA.Hybridization was at
42°C for three days.The filters were then washed three
times for 15 minutes with 2 X SSC, 0.1 % SDS at room
temperature and twice for 15 minutes with 0.2 x SSC, 0.1
% SDS at 52°C,Filters were exposed to x-ray film up to
three days at -80°C with intensifying screen.Plaques
that were detected by the CS-induced cDNA probe and not
by the cDNA probe derived from SFME cells cultured
serum-free were selected and rescreened four times. The
cDNA insert from one positive clone was subcloned in
pUC18.
Cloning of overlapping cDNA inserts. cDNA inserts
labeled with 32P using the random primer method were used
to screen various libraries for overlapping cDNAs:
(i) An oligo- (dT) primed library in lambda gtll prepared
from mRNA of TGF -Z treated SFME cells (Solem et al.,
1990,TGF -1was TGF-B1 from porcine platelets,R&D
Systems, Inc., MN), (ii) an oligo-(dT) primed library in
lambda gt10 prepared from mouse brain mRNA (from ATCC,
no. 37431), and (iii) a random primed mouse brain cDNA
library (Cat.# ML1024a, lot# 2411, Clonetech, CA)in
gt10.Filters were hybridized as described for the
differential screen, withtheexceptionthat55
hybridization was only overnight with 25-100x103 cpm/ml
probe.Filters were washed three times for 15 minutes
with 2 x SSC, 0.1 % SDS at room temperature, then two
times with 0.1 x SSC, 0.1 t SDS at 52°C.
Sequence analysis. Sequencing ofthe cDNA
inserts in pUC18 was performed by the Oregon State
University Center for Gene research using an automated
laser sequencer (ABI systems,CA).Sequence data bank
searchesweredonewiththeFastDBprogramof
IntelliGenetics.
Stability of TGF-13 regulated mRNAs in the presence
of U-amanatin.SFME cells were grown 24 hours in the
presence of TGF-S, the medium was then changed to medium
without TGF -Z,and a- amanatin(1µg /ml,from Sigma
Chemical Corp., MO) was added. TGF-13 was again added 15
minutesafter u-amanatin additiontohalfofthe
plates.After 0,3,6,8 hours of incubation RNA was
isolated,and Northern hybridization blot analysis
carried out.Probes were a cDNA piece that hybridized
to an approximately 8.5 kb, TGF-13 regulated mRNA (88),
a 13-actin cDNA probe (gift from Dr. J. Pipas, University
of Pittsburgh), and a cystatin C cDNA probe (Solem et
al., 1990).56
RESULTS
Identification of a CS/TGF-S regulated RNA in SFME
cells. Usingthetechniqueofdifferential
hybridization, we identified a RNA that is regulated by
calf serum or TGF-13 in SFME cells.Poly A-containing
RNA of SFME cells that were cultured 24 hours in the
presence of 10 t calf serum was purified to construct a
cDNA library in gtll.This library was screened by
dublicate filters with radiolabeled cDNA prepared from
poly A-containing RNA of CS or serum-free treated SFME
cells.Plaques that were labeled by the 'calf serum'
cDNA but not by the serum-free cDNA were rescreened in
four rounds. One final candidate clone contained a 183
by insert that hybridized to an approximately 8.5 kb RNA
that was present in total RNA of calf serum or TGF -1
treated SFME cells, but not in serum-free grown cells.
RNA size was estimated using the ribosomal bands as size
markers.We named this RNA S8.When probing total
cytoplasmic RNA of SFME cells faint bands of the size of
the 18S and 28S RNAs appeared on the Northern blot in
addition to the 8.5 kb band.This probably represents
hybridization to the ribosomal RNA and degraded L8 RNA,57
since those bands were absent when poly A-containing RNA
was probed.It may be that during gel electrophoresis
when the formamide of the loading buffer became diluted
degraded S8 RNA bound to ribosomal RNA and comigrated
with it.This effect could be minimized by chosing a
piece of cDNA for probe that was richer in G+C than the
restofcDNA,allowinghybridizationathigher
temperature (57°C).
The TGF -1regulated RNA is brain specific.A
Northern blot was performed using poly A-containing RNA
of different mouse tissues (brain, heart, kidney, liver,
lung, pancreas, skeletal muscle, spleen, and testis).
The183by cDNA insertfound by the differential
screening was used as probe.The 8.5 kb RNA was
detected in brain RNA, whereas no band was present in
the other tissue RNAs (figure 7).Balb 3T3 and 10 T 1/2
cells grown in the same culture medium as SFME do not
express the RNA even in the presence of TGF-S (figure
8).
Cloning the 3' part of the TGF-E, regulated RNA 118.
A Southern blot of mouse genomic DNA digested with58
various restriction enzymes was probed with the 183 by
fragment.For all restriction enzyme digests only one
band was visible (figure 9).This indicates that the
TGF -1regulated RNA represents a single copy gene.
Overlapping clones were obtained using
radiolabeled cDNA fragments as probes screening various
cDNA libraries.Cloning was straightforward until a
segment pieceofB1 mouserepetitiveelementwas
reached.From there on library screening gave clones
that had only the repetitive element in common and two
clones that were obviously of chimeric nature.While
their 3' sequences matched to the sequence of the 8.5 kb
RNA, their 5' sequences did not hybridize to the 8.5 kb
RNA and their 5' sequences were also not identical with
each other.The fact that the divergence begins within
the B1 element suggests that the element may be the site
of some recombinatory event, either during the synthesis
ofthe cDNA or in the vectors. This may not be
surprising since B1 elements are so abundant.When the
random primed mouse brain cDNA library was screened with
cDNA pieces containing B1 repeats approximately 2-5of
thecloneswerelabeled. Otherapproachesfor
additional sequence failed. An attempt to purify Z8 RNA59
by hybrid selection (Jagus et al., 1987) to construct a
S8 enriched cDNA library did not succeed.The cDNA
which was selected to bind the S8 RNA leaked from the
nylonmembraneandS8RNAeitherdidnotbind
specifically or could not be eluted from the membrane.
An approach to clone more sequence using PCR techniques
(Frohman, 1990) failed because one 18 specific primer
did not prime at the appropriate site.The combined
sequence from the overlapping cDNA pieces was compared
with sequences of large data banks.This did not reveal
any striking homology with known sequences, but pointed
to the presence of a B1 repeat, a rodent repetitive
element related to the Alu repeat in humans (Jelinek,
1982). In addition tothe B1repetitive element
sequence the sequence revealed a canonical
polyadenylation signal (Lewin, 1983), a poly-(A)-tail,
and a striking poly- (CA) stretch (CA19)(figures 17 and
18).Similar poly-(CA) streches are found in several
mRNA species (e.g.3'-untranslated tail of rat kidney
mitochondrial glutaminase mRNA,Shapiro et al., 1991).
The RNA f8 is specifically induced by TGF-S in
SFME cells.SFME cells were cultured in the presence of60
variouspeptidegrowthfactors(fibroblastgrowth
factor, platelet derived growth factor, nerve growth
factor, and transforming growth factor-S) at 10 ng /ml
for 48 h. RNA was then extracted and Northern blot
analysis was performed using a cDNA fragment as probe.
Only SFME cells treated with TGF -1expressedL8 RNA
(figure 10).In addition, 3,5,3'-triiodothyronine (T3)
at 10 nM and interferon-gamma at 10 ng/ml did not cause
an increase of S8 RNA (figure 11).A Northern blot of
RNA extracted from SFME cells treated with 10 ng/ml TGF-
13. for various lengths of time shows that an increase is
apparent 4 hr after addition of this factor (figure 12).
Addition of TGF -1for 24 hours and subsequent removal
for24hourscausedacompletereversionofthe
increase.TGF -Z at 1 ng /ml(40 pM) caused a maximal
response in SFME cells (figure 13).
Comparison of the TGF -Z regulation of the L8 RNA
and cystatin C mRNA in SFME cells.The effect of TGF-i3
on the stability of the 8.5 kb RNA was investigated in
SFME cells.SFME cells were first incubated with TGF-S
for8hour to increase the starting levelofthe
message.Then the cells were incubated with a-amanatin61
(1 µg /m1) to block further transcription (Drew et al.,
1989).The rate of depletion of the RNA was then
determined by Northern blot hybridization analysis of
cells incubated with or without TGF-S (10 ng/ml) in the
culture medium.That rate was then compared to the rate
ofdepletionofcystatinCmRNA underthesame
conditions. After 8 hours of incubation with a- amanatin
and TGF-S there was a depletion of cystatin C mRNA
without TGF -Z, but not with TGF-S (Solem et al., 1991,
unpublished data).However, there was no differential
in RNA stability with the 8.5 kb RNA (figure 14).In
contrast to cystatin C, the increase of level of Z8 RNA
in SFME was adversely affected by 1 µg /ml cycloheximide
in the culture medium (figure 15).
The regulation of S8 in some transfected Balb SFME
celllineswasinvestigated. Derivationsand
characteristcs of these lines are described in Shirahata
et al. (1990).Ha-ras Balb SFME cells and neu Balb SFME
cells were transformed by the human Ha-ras oncogene and
the rat neu oncogene respectively. Selection was growth
in the absence of EGF.Neo SFME were transfected with
aplasmid (pSVneo) containing the bacterial
aminoglycoside phosphotransferase gene under control of62
the SV40 early promoter (Southern and Berg, 1982) and
selectedinG418. Neo-neuSFMEwerederived by
cotransfection of a plasmid containing the rat neu
oncogeneunderthecontroloftheSV40promoter
(pSV2neuNT)(Bargmann et al., 1986 a,b) and the pSVneo
plasmid.Selection was in G418.
Interestingly, while Ha-ras-transformed SFME cells
expressed GFAP even in the absence of serum or TGF -f
(Sakai et al., unpublished data), they did not do so
with 18RNA. Surprisingly,two SFME cell lines
transfected with the neomycin resistance marker
pSVneo expressed 13.8 even in the absence of serum or TGF-
S.(figure 16).63
DISCUSSION
We identified a large, brain-specific RNA that is
regulated by TGF -Z and CS in SFME cells.Increase in
RNA level was observed within four hours after treatment
and was reversible upon removal of TGF -1. Picomolar
concentrations of TGF-S in the range of the Rd of the
known TGF -1receptors(Massague et al.,1990) were
sufficient to cause a significant increase.We named
this RNA L8.No other specific factor investigated
caused an increase of S8 in SFME cells.The RNA was
presentinpoly A-containingRNA,itcontainsa
polyadenylation signal and a poly-(A)-tail.It most
likely represents a messenger RNA molecule.Since the
combined sequence of the overlapping clones does not
reveal an open reading frame this sequence probably
belongs to the 3'-untranslated tail of the message.
The fact that the TGF-E, induced message is relatively
large and has a large 3'-untranslated tail is consistent
with the idea that it is a brain-specific message.
Brain-specific mRNAs are on average considerably larger
than mRNAs not specifically expressed in the brain and
also have large 3 ' -untranslated tails (Sutcliffe, 1988).64
Milner and Sutcliffe (1983) estimated from a randomly
collected set of rat brain mRNAs that the average length
of brain-specific molecules was around 4000 nucleotides,
and for the rarer class 5000 nucleotides, whereas the
average length of a nonspecific message was around 2000
nucleotides. Brain-specific mRNAsare very large
because they encode large proteins and have large 3'-
untranslated tails.Examples for such large brain-
specificmessagesarethoseofthemicrotubule
associated proteins (MAP1, MAP2, tau), the
neurofilaments, sodium channels I and II, and synapsin
2 (Milner and Sutcliffe,1983).18 RNA is of almost the
same size as reported for MAP2a and MAP2b mRNA which is
also expressed in cultured astrocytes and reactive
astrocytes(Couchie et al.,1985; Charriere et al.,
1991; Geisert et al., 1990).In a Northern blot of SFME
RNA probed with an endlabeled synthetic oligonucleotide
representing nucleotides 5716-5775 of MAP2 (Wang et al.,
1988) only the 6 kbp form of MAP2(MAP2c, Couchie et
al.,1985)was detectable, both in the absence and
presence of TGF-E, (data not shown).
Another notable feature of the Z8 message is the
presence of a B1 repetitive element as illustrated65
below.The 46 most 5' nulceotides of 88 that have been
cloned (upper line) are compared with sequence derived
from a B1 consensus sequence (lower line, Bains et al.,
1989).
CTGGGATTAA AGGTGTGCGC CACCACGCCC GGCTCTACAT TTTTC..
1111111111 111111111111111111111111 1 11
...CTGGGATTAA AGGCGTGTGC CACCACGCCC AGCTATATTT CTTAT..
The B1 repetitive element is 129-bp long (Krayev et
al.,1980) and belongs to a family of small moderately
repetitive sequences in the mouse genome (approx.105
copies per genome) and is related to the Alu family of
dispersed repeats in the human genome.Both of these
repetitive DNA families are evolutionary derived from
7SLRNA,theRNA molecule presentinthesignal
recognition particle which mediates the translocation of
secretory proteins across the endoplasmatic reticulum
(Ulluetal.,1984). These repeats may be mobile
elements and are found in mRNA precursor molecules as
well as cytoplasmic mRNAs (for review: Jelinek, 1982).
Some are also transcribed as discretely sized RNAs by
RNA polymerase III.Their function, if any, is unknown.66
When transcribed into RNA these repeats may form hairpin
structuresthatwerethebasisoftheirinitial
isolation (Krayev etal., 1980).
Another striking feature of the f8 sequence is a
homocopolymeric repeat consisting of CA doublets.
This structure has been identified as the sole unit of
another repeatedelementthatishighly conserved
throughout eukaryotic genome organization (Hamada et
al., 1982).It has been hypothesized that this element
has Z-DNA-forming potential in vivo (Hamada et al.,
1982) and that these sequences are potential targets for
recombination events (Hellman et al., 1988).
In addition to the S8 RNA, GFAP mRNA and cystatin
C mRNA also are known to be regulated by TGF-S in SFME
cells (Sakai et al., 1990; Solem et al., 1990).While
GFAP mRNA is brain-specific, cystatin C mRNA is also
found in most other tissues (Solem et al., 1990).The
time course and dose response of TGF -1regulation of
both L8 and cystatin C are almost identical.It is
especially noteworthy that the 1 8 ,cystatin C, and GFAP
mRNA increase is reversible.In contrast to cystatin C
regulationinSFME,S8regulationisaffected by
cycloheximide.TGF-S does not affect RNA stability of67
E8 in the same way aswith cystatin C.This may point
to different mechanisms of regulation.
To evaluate the physiological importance of the
TGF -f regulation of mRNAs in cells of the astrocytic
lineage, the presence of TGF-8 in the brain has to be
investigated.TGF-Z1 immunoreactivity has not been
found in the brain tissue of embryonicor adult mice,
but in tissue derived from mesenchyme, including the
meninges (Heine et al., 1987). By in situ hybridization
TGF -Z3 transcript-containing cells have been described
in the meninges, choroid plexus and the olfactory bulb,
but cells containing TGF -Z1 and TGF-Z2 mRNA were not
detectable in other parts of the brain(Wilcox and
Derynk,1988;Pelton etal.,1990). However,an
activity in acid/ethanol extract from adult mouse brain
that has properties of TGF -1 (Roberts et al., 1981) has
been identified.Clearly, the contribution of TGF-13, to
brain development and regulation has to be subject of
further studies.68
Figure 7:Tissue specifity of 18 RNA.Northern blot of
mRNA of different mouse tissues, 2 gg poly A-containing
RNA /lane, probed with the 183 by insert that was first
identified in the differential screen (clone A).Poly
A-containing RNA from(A)testis, (B)spleen, (C)
skeletal muscle,(D) pancreas,(E) lung,(F) liver,(G)
kidney,(H) heart,(J) brain.28S-
18S-
Figure 7
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Figure 8:Specific TGF-E, regulation of brain-specific
RNA B8 in SFME cells.Balb SFME cells (A, B), 10T1/2
cells(C,D), and Balb 3T3 cells(E,F)were grown
without (A, C, E) and with TGF -1(B, D, F) for 48 hours
in serum-free medium. Cytoplasmic RNAwas extracted and
Northern blot hybridization analysiswas carried out
using as probe a183 by cDNA clone identified as
representing a TGF-f3 regulated mRNA (20Ag RNA/lane).
The amount of RNA per lane was about equalas judged by
the ethidium bromide stained ribosomal RNAs.28S-
18S-
Figure 8
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Figure 9:Southern blot of mouse genomic DNA digested
with various restriction enzymes.The probe was the
183 by cDNA piece that was first identified in the
differential screen.(A), BglII; (B), PstI; (C), BamHI;
(D), HindIII; (E), EcoRI.The numbers at the left side
indicate the size markers in kbp.23.1
9.4
6.6
4.4
2.3
2.0
0.6
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Figure 10:TGF-Z specificity of regulation of a brain
RNA in SFME cells.SFME cells were grown in serum-free
medium for 48 hours in the presence of(A)10 ng /ml
nerve growth factor (NGF), (B) 10 ng/ml platelet-derived
growth factor (PDGF),(C)10 ng /ml fibroblast growth
factor (FGF),(D)10 ng/ml TGF -Z or(E)without any
additional peptide growth factor.Cytoplasmic RNA was
extracted and Northern blot hybridization analysis was
carried out using as probe a 3' HindIll fragment of a
cDNA clone (B, see figure 17) identified as representing
a TGF-8 regulated mRNA (20 gg RNA/lane).II
28S-
18S-
A BC DE
Figure 10
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Figure 11:TGF-13 specificity of regulation of f38.SFME
cells were grown 48 hours in thepresence of (A)10 nM
3,5,3' -L-triiodothyronine,(B)lng/mlTinterf er on or
(C) 10% CS.Cytoplasmic RNA was extracted and Northern
blot hybridization analysis was carried out.Upper
part: Probe was the 3' HindIll fragment of cDNA clone B
(see figure 17),identified as representing a TGF-8
regulated RNA, lower part: same blot probed with f3 -actin
cDNA.28S-
18S-
Figure 11
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Figure 12:Time course of regulation of SFME cellS8
RNA by TGF-S. SFME cells were treated with TGF -1
(lOng/m1), cytoplasmic RNAwas isolated and Northern
hybridization blot analysis carried out usingas probe
the 3' HindIll fragment of cDNA clone B, identifiedas
representing a TGF-S regulated RNA.(A), no TGF-S ,48
hour incubation;(B), TGF-S 4 hours incubation;(C),
TGF-S 8 hours; (D), TGF-S 24 hours; (E), TGF -f 48hours;
(F),TGF-S 24 hours, followed by 24 hour incubation
withoutTGF -Z.Bottom:thesameblot probed with
radiolabeled S-actin cDNA.28S-
18S-
ACTIN-
A B C D E
Figure 12
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Figure 13: TGF -f concentration dependence of regulation
of S8 RNA.SFME cells were treated with and without
TGF-B and cytoplasmic RNA was extracted after 24 hours,
the Northern blot was probed with the3'HindIll
fragment of clone B(see figure 17),identified as
representing a TGF -1 regulated RNA, and radiolabeled 13-
actin cDNA. (A), 10 ng/ml TGF -i;(B), 1 ng/ml TGF -i;
(C),0.1 ng /ml TGF -1;(D), 0.01 ng/ml TGF -L;(E), no
TGF -i.28S-
18S-
B
Figure 13
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Figure 14: Stability of TGF -1regulated RNAs in the
presence of u-amanatin. Probe was the3'HindIll
fragment of clone B, identified as representinga TGF-S
regulatedRNAinSFMEcells. Top:(A), 0hour
incubation;(B) three hours incubation in thepresence
of TGF-S and u-amanatin;(C), three hours a- amanatin
incubation in the absence of TGF -Z;(D),six hours
incubation in the presence of TGF-S and u-amanatin; (E),
six hours u-amanatin incubation in the absence of TGF-S;
(F), eight hours u-amanatin incubation in thepresence
of TGF -Z;(G), eight hours u-amanatin incubation in the
absence of TGF-S.28S
18S
actin
cystatin C
Figure 14
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Figure 15:Cycloheximide effect on TGF -Z regulationof
Z8 RNA.SFME cells were treated with TGF-S (10 ng/ml)
with or without cycloheximide (10µg /ml), cytoplasmic
RNA was analyzed in a Northern blothybridization using
as probe a cDNA piece of 18(3'HindIII fragment of
clone B, see figure 17) and S-actin.(A), cycloheximide
and TGF -1for 8 hours; (H), TGF-i3 only for 8 hours;(C),
cycloheximide only for8hours;(D),noTGF-13or
cycloheximide.o
0
co
a
ch
co
oi
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Figure 16: TGF-i3 regulation of E8 RNA in various
transfected SFME cell lines.(A), SFME cells grown 24
h in the presence of 1ng /ml TGF-8;(B), neu-c1.2-1
SFME, no CS or TGF-E; (C), neo-neu-c1.8,no CS or TGF-Z;
(D),neo-SFME, no CS or TGF-E;(E), Ha-ras-mvc-c1.1
SFME, no CS or TGF -Z;(F) ,Ha-ras-c1.10 SFME, no CSor
TGF-E;(G), Ha-ras-c1.4 SFME, no CSor TGF-E;(H), Ha-
ras-c1.1 SFME, no CS or TGF-E.Probe was the 3' HindIll
fragment of clone B.28S-
18S-
A BCDE FG H
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Figure 17:Map of cloned cDNA inserts representing 88.
5'positionistotheleft,3'totheright.
Restriction sites,extend of overlaps and sequence
features are indicated.Clones C and D are chimeras.MOM
,11'NMI
61
sequence
mndm
IIv
(CA)
19
EcoRl HindlIl
V
14V
Z
1301Y
adenyiation
signal
II
B
A
C
D(1 KbP)
E(2 KbP)
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Figure 17
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Figure 18:Partial cloned sequence of S8.Part of the
B1 sequence, the CA repeat, and the polyadenylation
signal are underlined.Only sequence that was found in
two independent phage clones is shown.CTGGGATTAA
GTGAAATAAT
ACTTCCCAAG
AATCTATGAA
GGGTAAAGAT
CATGTTTTAA
TCCCTGTGCT
CACGGCAAAC
GTGGGTGATT
ACAAGCACAA
GGTCAGGGCA
CCTAAGTGTT
GGCAGTTACT
CCTCTCAGCA
AGAGAAAGAC
CCTTCTGTGC
CAGTCTGGCC
TCCTTCTGCC
CTGGTGTATA
TAAATGTTCT
ACTCTGTCAA
TTATCTGTGC
CTTGATTGTG
TCCTTACCTG
CACGGAGCAG
CGTAAAGGTC
TTCAGAAGGA
CTGGGGCTCA
GGCATGCTTT
TCCCTGGTGT
AGAATGGCTA
AGCTTTGATG
GACTTATTGG
AAAAAAAA
figure 18
AGGTGTGCGC
CCACTTTGGA
CCAGGGACAG
TTTGTGTTAA
GCTGCATAAG
AAGTGAAAAG
GAGACTATAG
CCTTAAAGGG
CTCCAACACA
AATAAATAAG
GGGATGGGTG
TACTGAGCTG
GAATAGAAGC
GCCCACGTGG
AAAGTTACAG
ATTATAATTA
TTGAATTCAC
TCAGTTTCCC
CAATGCTAGG
ACACCTGAGC
CTGAGCTACA
TTCGAACGCT
CTCCAAATTT
CTGTCACACA
ACTTGGGAAA
CCTGTGACTG
ACCACACCAA
GAGGTTCTTC
AGGCTTTTCT
GTCTGCTTGG
CAGGTTCTGC
TTCCGTGGAT
ACA'rri-VAAT
CACCACGCCC
TTCCCTCTTC
GGTCCCACAG
AGCCACAGTG
CCTGAAGAAG
CCAGGCAGGG
GAAGCTCATG
TAGCATTTGA
CGCACAACCC
TAAAAATTTC
CACAGGTTCT
CATTGCTCAC
CGTGTAAAGC
TCCTTAGTCT
ACTACGATAG
CTGTAAGTGT
TCGGTAGCTG
AAGTACTAAA
GATGGAACCC
TCCAAGTACT
AGTACTCTGT
ACCAACTTAG
TGCTTTATGT
CACACACACA
TGGTTGAAAA
GGGACAAAGC
TCCCCTGCTG
CTAGCCCCTG
GGACTGGAGC
GCCAGTATGC
TGGGTTTTGT
CTGTGCTATC
AAAAAI
GGCTCTACAT
CCATCTACAT
AGCCCATGCA
GAGCCTAAGC
TCCGTTTAAG
TGTGAACCCT
AGCCAGCTAG
CCTCCACTGC
TCTCCCCCCA
AAAAACTGTA
GGGGTCCATG
AGGAGGTAAT
CTTGTGAGAT
CCCATTTCCA
AGGAGCTAGA
TGATTTTTTG
AGGATAACCT
ACGGCAGGTA
AGAGATITGT
CTGTCAACTG
CAACTGAGCT
TTCGATTCGC
TTAAGGGAAG
CACACACACA
AAGCAAACTG
TTCTTGGTAA
GGGATTGAGG
CACTGCCTGC
CTCATCTCCA
GGGAGGAGTG
TTTGTTTTTG
TGACACTGTG
TAACAGTTAA
TTTTCAAAAT
CCCAGAAAAG
GTGTGGGTAG
TTAGCCCTGT
CCCTGGGACC
GGTGCCAGCA
CCTGGAGGAT
ACACTACAGT
CACACACTGC
GGATTGGGTG
CCCAGCTCTT
GAAAGCCTGG
GCCCTTGAAT
CTTGATTATA
GCAAGAATTT
GACAGGGCCT
TAAAGTCTGA
TGCACTATGA
GCATACTAAG
AGCTCCAAGC
CCAAGCACTC
AAACCCTGGT
AGACCTAAAA
CACACACACA
GACCCTGAAC
CATTTTCTAA
GCGAGGCCTG
TCCATGGAGG
GCTTTCCCCC
TGTATGTGCG
CTGGG
GATGTTAATG
AAAAAAAAAA
9192
Chapter IV
CONCLUSIONS AND PERSPECTIVES
SFME cells were derived in serum-free medium.
The study of effects of serum on these cells lead to
severaldiscoveries: (i)Thereversiblegrowth
inhibition of SFME cells by serum factors,(ii)the
resistance of transformed SFME cells to this inhibition,
(iii) the appearance of markers of differentiation in
SFME cells when exposed to serum.
Plasmagrowthinhibitoryactivity. Growth
inhibitory activity was also found in human plasma.
The characterization and partial purificationof the
growth inhibitory activity of human plasma indicated
that a macromolecular entity, probably a polypeptide, is
a major contributor to the growth inhibitory activity.
However, it seems that several components of the plasma
interacttocreatetheinhibitoryeffectof
unfractionated plasma.
Most known growth inhibitory factors (e.g. TGF-Z)
were not purified as growth inhibitors,but other
activites associated with those factors were used to93
identify and assay them, and their growth inhibitory
activities were discovered later.The difficulties of
interpreting growth inhibition assays and the possible
artifactual effects make the direct purification ofa
growth inhibitor problematic, especially if one usesa
complex mixture of substances such as plasma as starting
material.It may,therefore, be useful to identify
other activites that may be associated and copurify with
thegrowthinhibitoryactivity. Thestriking
morphological change of the SFME cells when exposed to
the Sephadex G-50 purified preparation may lead to such
a 'foothold'.
TGF -Z regulated brain RNA. Another effect of calf
serum on SFME cells that was investigated in this thesis
is the induction of a large, brain-specific message in
SFME cells. This effect could be reproduced with TGF-S,
aserumcomponent. Thisfindingconfirmsthe
neuroectodermal origin of SFME cells and their in vitro
differentiation under the influence of TGF-S.
GFAP and cystatin C,a protease inhibitor, are other
molecules that are regulated by TGF-S in SFME cells.
GFAP (Eng ,1988) and protease inhibitors (e.g. Wagner et
al.,1989; Abraham et al., 1988) are associated with94
pathological states of the brain.It is therefore not
unreasonable to speculate that L8 may be of clinical
interest,too. It may therefore beimportantto
characterize this message by cloning and sequencing more
of the gene until a function can be attributed to it.
The presence of repetitive elements in the gene may
require the developement of special techniques to manage
this task.Since repetitive elements are common in
genes and mRNAs (maybe especially in the large mRNAs of
the brain), such techniques could be of great general
interest.
Serum and SFME.The multiple and complex effects
serumhasonSFMEcellssuggestsphysiological
importanceofserumorserumcomponentsinthe
regulation of the hypothetical in vivo counterparts of
these cells.Defining the in vivo fates and properties
of such cells may yield new and important insights.95
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